INTASYL

Phio Pharmaceuticals Showcases PH-762 Skin Cancer Trial Progress

KING OF PRUSSIA, Pa., May 12, 2026 Phio Pharmaceuticals announced that company leadership will participate in a virtual fireside...

By cGxPwire Editor
May 14, 2026

Bio-Pharma

Phio Pharmaceuticals Reports Positive PH-762 Skin Cancer Data

KING OF PRUSSIA, PENNSYLVANIA, March 23, 2026 Phio Pharmaceuticals Corp. has announced the presentation of positive clinical study results...

By cGxPwire Editor
March 24, 2026

Bio-Pharma

Phio to Present INTASYL siRNA Advances at ATUSA 2025

Dateline IntroductionNovember 17, 2025 — Marlborough, Massachusetts — Phio Pharmaceuticals Corp., a clinical-stage biopharmaceutical company advancing RNA-based immuno-oncology therapeutics,...

By cGxPwire Editor
November 18, 2025

Bio-Pharma

Phio Pharmaceuticals Advances siRNA Immunotherapy in Skin Cancer with INTASYL PH-762

Dateline — King of Prussia, Pennsylvania, November 7, 2025:Phio Pharmaceuticals Corp. (NASDAQ: PHIO) has announced new clinical data from...

By cGxPwire Editor
November 9, 2025

Bio-Pharma

Phio Pharmaceuticals Strengthens Governance with New Lead Director

King of Prussia, Pennsylvania – October 31, 2025 — Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biopharmaceutical company developing...